OC
AZN icon

Oarsman Capital’s AstraZeneca AZN Stock Holding History

Oarsman Capital’s Portfolio AZN Stock Details AZN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$3.26M Buy
16,553
+2,231
+16% +$430K 0.41% 41
2025
Q4 		$2.63M Buy
14,322
+1,591
+12% +$279K 0.34% 52
2025
Q3 		$1.95M Buy
12,731
+1,066
+9% +$161K 0.27% 64
2025
Q2 		$1.63M Sell
11,665
-188
-2% -$26.3K 0.26% 77
2025
Q1 		$1.74M Buy
11,853
+1,863
+19% +$270K 0.31% 68
2024
Q4 		$1.31M Sell
9,990
-575
-5% -$80.5K 0.23% 83
2024
Q3 		$1.65M Buy
10,565
+1,571
+17% +$254K 0.3% 70
2024
Q2 		$1.4M Buy
8,994
+1,972
+28% +$297K 0.31% 71
2024
Q1 		$951K Sell
7,022
-716
-9% -$94.8K 0.23% 92
2023
Q4 		$1.04M Buy
7,738
+187
+2% +$24.3K 0.28% 85
2023
Q3 		$1.02M Buy
7,551
+27
+0.4% +$3.69K 0.43% 64
2023
Q2 		$1.08M Sell
7,524
-39
-0.5% -$5.74K 0.47% 58
2023
Q1 		$1.05M Buy
7,563
+673
+10% +$90.5K 0.49% 55
2022
Q4 		$934K Sell
6,890
-1,680
-20% -$211K 0.48% 61
2022
Q3 		$940K Sell
8,570
-125
-1% -$15.9K 0.5% 57
2022
Q2 		$1.15M Sell
8,695
-190
-2% -$24.9K 0.57% 53
2022
Q1 		$1.18M Buy
8,885
+312
+4% +$37.4K 0.46% 65
2021
Q4 		$999K Buy
8,573
+73
+0.9% +$8.59K 0.39% 79
2021
Q3 		$1.02M Sell
8,500
-8
-0.1% -$931 0.41% 78
2021
Q2 		$1.02M Buy
+8,508
New +$933K 0.4% 80

Other funds holding AZN

IA
Investor AB Stockholm, Sweden $15.1B AUM 29.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Legal & General Group
Legal & General Group London, United Kingdom $432B AUM 29.4% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
VAM
Vanguard Asset Management London, Ec4n 8af $117B AUM

Oarsman Capital's AZN Position: Q1 2026 in Review

Oarsman Capital increased its AstraZeneca (AZN) stake by 16% in Q1 2026, buying an estimated $430K and bringing the position to 16,553 shares worth $3.26M. The position accounts for 0.41% of the portfolio, ranked #41.

Oarsman Capital first reported a position in AZN in Q2 2021 and has held it in 20 quarters since. 1,377 funds tracked by Wall St. Rank hold AZN as of Q1 2026.

  • Oarsman Capital held 16,553 shares of AstraZeneca worth $3.26M as of Q1 2026.
  • Oarsman Capital bought 2,231 AstraZeneca shares in Q1 2026, an estimated $430K.
  • AstraZeneca made up 0.41% of Oarsman Capital's portfolio in Q1 2026, its #41 holding.
  • Oarsman Capital first reported a position in AstraZeneca in Q2 2021 and has held it in 20 quarters since.
  • 1,377 funds tracked by Wall St. Rank held AstraZeneca as of Q1 2026.

Based on Oarsman Capital's 13F filing for Q1 2026, filed 28 Apr 2026.